Regeneron Pharmaceuticals Inc
(LTS:0R2M)
$
676.38
+3.995 (+0.59%)
Market Cap: 70.47 Bil
Enterprise Value: 64.42 Bil
PE Ratio: 16.38
PB Ratio: 2.25
GF Score: 87/100 Regeneron Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript
May 30, 2023 / 04:30PM GMT
Release Date Price:
$721.82
(+0.17%)
Tyler Martin Van Buren
TD Cowen, Research Division - MD & Senior Equity Research Analyst
All right. We'll give it a couple of seconds for everyone to join. Okay. So with that, welcome, everyone, again, to the TD Cowen's Fourth Annual Oncology Innovation Summit: Highlights for ASCO and EHA. My name is Tyler Van Buren, senior biotech analyst here at TD Cowen. For our next session, we're very pleased to have a fireside chat with Regeneron. And it's my sincere pleasure to introduce Izzy Lowy, Senior Vice President of Solid Organ Oncology Development; and Andreas Sirulnik, Senior Vice President of Heme-Onc Development. Izzy and Andreas, it's a privilege to have you both here. Thank you very much for joining me.
L. Andres Sirulnik
Regeneron Pharmaceuticals, Inc. - SVP of Translational & Clinical Sciences, Hematology
Thank you for having us, Tyler.
Tyler Martin Van Buren
TD Cowen, Research Division - MD & Senior Equity Research Analyst
Ryan, Head of IR -- Ryan Crowe, Head of IR, thank you very much for being
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot